SecBot SecBot

HUMA

Humacyte, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001818382 Biotech & Drug Discovery
$0.4041 −0.03 (−7.10%)
Oct 26 4:00 PM ET · prev $0.4350
Market cap
$114.8M
Micro cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
$1.13
+178% · range $0.5000–4.00
Next earnings
Nov 6
in 11 days · EPS est. −$0.08
1 year
−75.9%
from $1.68 · Oct 27
30 days
−26.1%
from $0.5470
52-week range
$0.3540–1.70
−76% from high · low Oct 14
Avg volume 20D
6.46M
Oct 15 spike 20.79M
Short interest
29.40M
≈10.6% of shares · −7.6%
Days to cover
7.3
at average volume
Insider net
+$7.9K
3 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 6, 2026
Strongest BULLISH Humacyte provided a Q3 2026 commercial update highlighting accelerating Symvess adoption, with hospitals…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    3 insiders bought $90.2K at an average $0.7657. 2 insiders sold $82.3K. Price is 47% below their cost.

  • InstitutionsMIXED

    Q2 2026: 18 added (0 new), 19 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.083 → −$0.083 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −7.6% to 29.40M shares. 7.3 days to cover, ≈10.6% of shares.

  • TrendDOWNTREND

    25% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD10,107,679$7.9M
BlackRock, Inc.TRIM4,839,929$3.8M
GEODE CAPITAL MANAGEMENT, LLCTRIM2,185,225$1.7M
MILLENNIUM MANAGEMENT LLCDOUBLED1,909,049$1.5M
SUSQUEHANNA INTERNATIONAL GROUP, LLPADD1,699,243$1.3M
STATE STREET CORPTRIM842,537$657.5K
BANK OF AMERICA CORP /DE/ADD578,592$451.3K
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM568,521$443.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy3Buy6Hold2Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +178%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 7, 2026Barclays
INITIATE
INITIATEEqual-Weight
Aug 13, 2026Benchmark
MAINTAIN
MAINTAINSpeculative Buy
Jul 28, 2026BTIG
REITERATE
REITERATEBuy
Jun 17, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Jun 16, 2026BTIG
REITERATE
REITERATEBuy
Jun 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$90.2K
bought · 3 insiders
$82.3K
sold · 2 insiders
−47.2%
vs their $0.7657 cost
DateInsiderTypeValue
Oct 6, 2026
COWARD D SCOTT
Director
AWARD125,000 sh
Oct 6, 2026
Kuznik Paul Brian
Director
AWARD125,000 sh
Sep 14, 2026
Jones Keith Anthony
Director
BUY$5.6K
Aug 20, 2026
Jones Keith Anthony
Director
BUY$6.9K
Aug 17, 2026
Jones Keith Anthony
Director
BUY$17.8K
Jun 11, 2026
Bamforth John Philip
Director
AWARD80,000 sh
Jun 11, 2026
Dougan Brady W
Director
AWARD0 sh
Jun 11, 2026
Brown Emery N.
Director
AWARD80,000 sh

Earnings setup

Estimates
Nov 6
reports in 11 days
−$0.08
EPS estimate, this quarter
+1%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.10–-$0.06+0.0%$770.0K
Next Q-$0.08-$0.11–-$0.05+0.0%$1.8M
Current FY-$0.40-$0.46–-$0.34+0.0%$3.5M
Next FY-$0.25-$0.30–-$0.18+0.0%$21.7M
Congressional trades
HUMA trades disclosed by members of Congress, with disclosure delay.
0 members(excl. 5 subscriber-only trades) · 3 buys / 2 sells
DateMemberTypeAmountDisclosed
May 3, 2024🔒 Fresh data, subscribers onlySELL
May 3, 2024🔒 Fresh data, subscribers onlySELL
Mar 21, 2024🔒 Fresh data, subscribers onlyBUY
Mar 21, 2024🔒 Fresh data, subscribers onlyBUY
Mar 21, 2024🔒 Fresh data, subscribers onlyBUY

Short side

FINRA· Sep 30, 2026
29,399,293
shares short
-7.6%
vs prior settlement
7.3
days to cover
≈10.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Humacyte provided a Q3 2026 commercial update highlighting accelerating Symvess adoption, with hospitals ordering the…
PRESS-RELEASE — Impact 5/10
Oct 15, 2026 Earnings
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of
Oct 6, 2026 Insider
COWARD D SCOTT was granted 125,000 shares
Director
Oct 6, 2026 Insider
Kuznik Paul Brian was granted 125,000 shares
Director
Sep 14, 2026 Insider
Jones Keith Anthony bought 10,000 shares
Director @ $0.5620 ($5.6K)
Aug 19, 2026 Press
Humacyte announced publication of one-year Phase 3 V007 trial results in The Lancet Digital Health, showing ATEV…
Impact 6/10
Aug 12, 2026 SEC
Humacyte reported Q2 2026 results with product revenue of $0.4M (up from $0.1M YoY) but a net loss of $36.8M, missing…
8-K — Impact 6/10
Aug 12, 2026 SEC
Humacyte reported Q2 2026 EPS of -$0.09, beating consensus of -$0.10 by 12.9%, with Symvess product revenue of $0.4M…
PRESS-RELEASE — Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 6, 2026
Earnings date
HUMA Q3 2026 Earnings Scheduled — 2026-11-06
Recent
Oct 15, 2026
Earnings
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30…
Sep 28, 2026
Press release
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing…
Sep 9, 2026
Press release
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months –
Aug 24, 2026
Press release
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
Aug 19, 2026
FDA
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –

SecBot reports

9 filings · 7 press releases · 3 bullish · 1 bearish · 2 mixed · 3 neutral
All HUMA filing & press-release reports (16)